PHASE-II STUDY TO EVALUATE ACTIVITY OF DEXRAZOXANE CARDIOXANE IN ORDER TO PREVENT CARDIAC TOXICITY IN PATIENTS WITH BREAST CANCER AND TREATED WITH ANTHRACYCLINE
- Conditions
- To evaluate activity of Dexrazoxane in order to prevent cardiac toxicity in patients with breast cancer and treated with anthracyclineMedDRA version: 6.1Level: PTClassification code 10057654
- Registration Number
- EUCTR2005-003217-32-IT
- Lead Sponsor
- AZIENDA USL DI FORLI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 45
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Dexrazoxane utilize to prevent anthracycline-induced cardiotoxicity in breast cancer patients?
How does Dexrazoxane compare to standard cardioprotective agents like beta-blockers in preventing cardiac toxicity during anthracycline chemotherapy?
Are there specific biomarkers that can identify breast cancer patients most likely to benefit from Dexrazoxane cardioprotection?
What are the known adverse events associated with Dexrazoxane use in anthracycline-treated breast cancer patients and how are they managed?
What combination therapies or alternative cardioprotective drugs are being explored alongside Dexrazoxane for anthracycline-induced cardiotoxicity prevention in oncology?